Pfizer to Pay $14 Million to Use Santaris Technology
This article is for subscribers only.
Pfizer Inc. agreed to pay $14 million to use closely held Santaris Pharma A/S’s technology to develop drugs that target ribonucleic acid, a new avenue of research, expanding on an earlier accord with Wyeth.
Santaris may get up to $600 million if certain research milestones are met, as well as royalties on sales of products that may be developed for up to 10 targets picked by Pfizer, Hoersholm, Denmark-based Santaris said in a statement today.